Tropical diseases

Freshpet Voluntarily Recalls One Lot of Freshpet® Select Small Dog Bite Size Beef & Egg Recipe Dog Food Due to Potential Salmonella Contamination

Saturday, June 12, 2021 - 6:51pm

BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.

Key Points: 
  • BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.
  • Our Freshpet Team had designated this single lot for destruction, but it was inadvertently shipped to retailers in limited geographic markets between June 7 and June 10, 2021.
  • Rarely,Salmonellacan result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
  • Sell by Date, along with UPC code and lot code, can be found on the bottom and back of each bag.

Global Neglected Tropical Diseases Diagnosis Market Research Report 2021 - ResearchAndMarkets.com

Friday, June 11, 2021 - 1:20pm

The "Neglected Tropical Diseases Diagnosis - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neglected Tropical Diseases Diagnosis - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Neglected Tropical Diseases Diagnosis estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2027, growing at a CAGR of 4% over the period 2020-2027.
  • Conventional, one of the segments analyzed in the report, is projected to record 3.7% CAGR and reach US$4.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 6.4% CAGR
    The Neglected Tropical Diseases Diagnosis market in the U.S. is estimated at US$1.6 Billion in the year 2020.

Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases

Friday, June 4, 2021 - 2:00pm

The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.

Key Points: 
  • The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.
  • Auransa is an AI-driven biotech company, with a pipeline of novel compounds for various diseases.
  • POLARISqb built the first drug discovery platform using quantum computing, making the process ten times faster.
  • We are thrilled to be able to combine our technology with Auransa's and tackle neglected diseases affecting women.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Wednesday, June 2, 2021 - 12:00pm

"As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.

Key Points: 
  • "As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.
  • Today's news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies.
  • We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health."
  • "Kamada is excited to have a HRIGthat can treat peopleof all ages in the U.S. with the FDA-approved label expansion for KEDRAB," said Amir London, Chief Executive Officer of Kamada.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Wednesday, June 2, 2021 - 12:00pm

The new updates to the KEDRAB label are based on data from the KEDRAB U .

Key Points: 
  • The new updates to the KEDRAB label are based on data from the KEDRAB U .
  • As the U.S. markets first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.
  • Todays news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies.
  • We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health.

Article - Travel safely with the EU Digital Covid Certificate

Thursday, May 27, 2021 - 8:01pm

How does the EU Digital Covid Certificate work?

Key Points: 
  • How does the EU Digital Covid Certificate work?
  • The certificate will make it easier for you to travel safely through the EU by showing that you have been vaccinated, had a negative test result or recovered from Covid-19 in the last six months.
  • The system will be in place for 12 months and cover all 27 EU countries as well as Iceland, Norway and Lichtenstein.
  • You dont have to have the certificate to travel - national requirements would then remain in place - but having it should make travelling easier.

Imhealthytoday Launches Vaccination Wallet

Monday, May 24, 2021 - 1:26pm

MIAMI, May 24, 2021 /PRNewswire/ --Imhealthytoday, a leading Covid-19 protection program headquartered in Miami, Florida, announces the launch of Vaccination Wallet, their latest screening tool now included in their program.

Key Points: 
  • MIAMI, May 24, 2021 /PRNewswire/ --Imhealthytoday, a leading Covid-19 protection program headquartered in Miami, Florida, announces the launch of Vaccination Wallet, their latest screening tool now included in their program.
  • Imhealthytoday is a turn-key complete solution combining proprietary screening and monitoring algorithms, integrated telehealth, expedited COVID-19 testing, contact tracing, population health status real-time reporting, visitor screening, on-site vaccination, surveillance testing, and now with the addition of the Vaccination Wallet tool; it offers secure real-time vaccination tracking.
  • The Vaccination Wallet is an innovative tool that enables Imhealthytoday members to digitally store their vaccination records eliminating the need to carry sensitive information.
  • In-depth vaccination information like vaccination certificates, date, dose stage, and renewal date will be available at the Population Health Status Dashboard.

12-year-old Girl Publishes The GIVID, a "Captivating" Novella About the Future of COVID Vaccination; Offers Copy to President Biden, VP Harris, Speaker Pelosi, Congress and All Governors

Wednesday, May 19, 2021 - 1:36pm

A GIVID is the document given by the government after one has received COVID vaccination.

Key Points: 
  • A GIVID is the document given by the government after one has received COVID vaccination.
  • A CDC Vaccination Card is an example of a GIVID.
  • In the future, 2024, to be exact, COVID-19 has progressed, and governments worldwide are mandating COVID vaccination for everyone.
  • Individuals receive a GIVID in the form of a bar code on a card after they have been vaccinated.

Global Malaria Markets, Epidemiology and Patient Flow Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:11am

b'The "Global Malaria Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Malaria Epidemiology and Patient Flow Analysis - 2021, provides Malaria epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Malaria Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Malaria Epidemiology and Patient Flow Analysis - 2021, provides Malaria epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Malaria patients, history of the disease at the population level (Malaria prevalence, Malaria incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Malaria patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Malaria market sizing, assessing market potential, and developing drug forecast models\nIdentify Malaria patients segments through age groups, gender, and disease sub-types\n'

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

Tuesday, May 11, 2021 - 6:08pm

b'GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer.

Key Points: 
  • b'GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer.
  • GeoVax\xe2\x80\x99s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers.
  • The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.
  • The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.\n'